Evidence map›Paper›PMID 41657775›Full record

ReviewFrontiers in pharmacology2025

Advances in research on the effects of medicinal and edible substances on lung cancer: an updated review.

Ying Yang, Lingli Jiang, Ke Li, Genming Zhang, Junpeng Wang, Daorui Li

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ying YangOncology Department, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
Lingli JiangOncology Department, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
Ke LiOncology Department, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
Genming ZhangOncology Department, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
Junpeng WangGeneral Surgery Department, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
Daorui LiOncology Department, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer, as one of the malignant tumors with the highest morbidity and mortality worldwide, poses a serious threat to human life and health. Despite the fact that there have been significant advances in the modern medicine treatment of lung cancer, the problem of drug resistance and the potential toxic side effects associated with the respective treatment still restrict the clinical efficacy and the amelioration of patients'quality of life. Based on this background, the therapeutic value of traditional Chinese medicine (TCM) as an adjuvant has become increasingly prominent. Among these, medicinal and edible substances have garnered growing research attention for the adjuvant treatment of lung cancer, owing to their wide sources, fewer side effects, and multi-pathway anti-tumor potential. Medicinal and edible substances abound with polysaccharides, flavonoids, terpenoids, saponins, polyphenols, and other bioactive substances. They are pivotal in the prevention and treatment of lung cancer through multiple mechanisms, including anti-inflammatory effects, antioxidant effects, immunomodulation effects, inhibition of tumor angiogenesis effects, and cell regulation effects. In this review, the pharmacological action of active components in medicinal and edible substances and the mechanism of action in the treatment of lung cancer were reviewed systematically, and the research direction of medicinal and edible substances in the field of lung cancer in the future was prospected, in an effort to provide theoretical reference for promoting its in-depth application in the comprehensive treatment of tumors, as well as for its complementarity of strengths and coordinated advancement with modern medicine.

Indexed as

active ingredientslung cancermechanismmedicinal and edible substancestraditional Chinese medicine

Identifiers

PMID41657775
PMCPMC12872840

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.